Company news

Tenaya Therapeutics, Inc. news in 2026

Tenaya Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

November 4, 2026

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

September 14, 2026

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 4, 2026

Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

June 29, 2026

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

June 3, 2026

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

June 2, 2026

Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026

May 29, 2026

Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC

May 15, 2026

Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026

April 27, 2026

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 10, 2026

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

March 8, 2026

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

March 4, 2026

Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026

March 2, 2026

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

January 9, 2026

Decks in 2026